[
  {
    "ts": null,
    "headline": "Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
    "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.",
    "url": "https://finnhub.io/api/news?id=cfb8ebec02a03e99955b99f8e735218e7aaf4612fa7731344fee6369e1937b2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765130338,
      "headline": "Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
      "id": 137726759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.",
      "url": "https://finnhub.io/api/news?id=cfb8ebec02a03e99955b99f8e735218e7aaf4612fa7731344fee6369e1937b2b"
    }
  },
  {
    "ts": null,
    "headline": "Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA",
    "summary": "WILMINGTON, Del., December 07, 2025--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA",
    "url": "https://finnhub.io/api/news?id=cc66364ebfa154a223c179274b6fec0950cc08db5fac17f20fd06e46722695b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765117800,
      "headline": "Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA",
      "id": 137726761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 07, 2025--Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA",
      "url": "https://finnhub.io/api/news?id=cc66364ebfa154a223c179274b6fec0950cc08db5fac17f20fd06e46722695b5"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025",
    "summary": "WILMINGTON, Del., December 07, 2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025",
    "url": "https://finnhub.io/api/news?id=ba40f1ec3aa87ef5249b31625347d9fc9968e3aaa11465e22344949566ea127c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765117800,
      "headline": "Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025",
      "id": 137726760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 07, 2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2025",
      "url": "https://finnhub.io/api/news?id=ba40f1ec3aa87ef5249b31625347d9fc9968e3aaa11465e22344949566ea127c"
    }
  }
]